Publication | Closed Access
Iodine I 131 Tositumomab for Patients With Follicular Non-Hodgkin’s Lymphoma (NHL): Overall Clinical Trial Experience by Histology
20
Citations
0
References
2000
Year
Unknown Venue
Iodine-131 TositumomabImmunodeficienciesImmunologyPathologyImmunotherapeuticsNew RadioimmunotherapyImmunotherapyHematological MalignancyRadiation MedicineOncologyHematologyRadiopharmaceutical TherapyRadiation OncologyNuclear MedicineMolecular OncologyCancer ResearchHealth SciencesLymphoid NeoplasiaPhase I-iii StudiesHistopathologyImmune SurveillanceAutoimmunityMedicine
Iodine-131 tositumomab (Bexxar) is a new radioimmunotherapy in development for the treatment of patients with low-grade or transformed low-grade non-Hodgkin’s lymphoma. The data from five phase I-III studies, which enrolled patients with low-